Avalo Therapeutics Inc(AVTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AVTX Avalo Therapeutics Inc

交易中 07-08 14:43:55 EDT

18.93

-0.32

-1.66%

最高19.84	最低18.36	成交量73.68万
今开18.97	昨收19.25	日振幅7.69%
总市值9.95亿	流通市值7.62亿	总股本5,257万
成交额1,401万	换手率1.83%	流通股本4,027万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AVTX","market":"US","secType":"STK","nameCN":"Avalo Therapeutics Inc","latestPrice":18.93,"timestamp":1783536233191,"preClose":19.25,"halted":0,"volume":736849,"delay":0,"changeRate":-0.016623376623376637,"floatShares":40269500,"shares":52565600,"eps":-5.57,"marketStatus":"交易中","change":-0.32,"latestTime":"07-08 14:43:55 EDT","open":18.97,"high":19.84,"low":18.36,"amount":14011537.42252,"amplitude":0.076883,"askPrice":18.95,"askSize":200,"bidPrice":18.91,"bidSize":402,"shortable":3,"etf":0,"ttmEps":-5.57,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1783540800000},"marketStatusCode":2,"adr":0,"listingDate":1447390800000,"exchange":"NASDAQ","adjPreClose":19.25,"preHourTrading":{"tag":"盘前","latestPrice":19,"preClose":19.25,"latestTime":"09:29 EDT","volume":236,"amount":4483.910792,"timestamp":1783517399999,"change":-0.25,"changeRate":-0.012987,"amplitude":0.015117},"postHourTrading":{"tag":"盘后","latestPrice":19.008,"preClose":19.25,"latestTime":"19:43 EDT","volume":2322,"amount":44691.22,"timestamp":1783467839967,"change":-0.242,"changeRate":-0.012571,"amplitude":0.012571},"volumeRatio":0.500955,"impliedVol":0.8196,"impliedVolPercentile":0.3785},"requestUrl":"/m/hq/s/AVTX","defaultTab":"news","newsList":[{"id":"1151106505","title":"Leerink Partners首次覆盖Avalo Therapeutics，给予“跑赢大盘”评级，目标价38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1151106505","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151106505?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:55","pubTimestamp":1783335313,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners日前宣布，正式启动对生物制药公司Avalo Therapeutics Inc.的研究覆盖，并给予其股票“跑赢大盘”的评级。分析师为该股设定的目标价格为每股38美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188200472","title":"Avalo Therapeutics扩充管线，引入长效新一代抗IL-1β抗体AVTX-010","url":"https://stock-news.laohu8.com/highlight/detail?id=1188200472","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188200472?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:06","pubTimestamp":1781607986,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics公司宣布其研发管线迎来新成员——AVTX-010。这是一款长效的新一代抗白细胞介素-1β（IL-1β）抗体，旨在为相关疾病领域提供创新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169747777","title":"美银全球研究首次覆盖Avalo Therapeutics，给予买入评级及35美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1169747777","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169747777?lang=zh_cn&edition=full","pubTime":"2026-06-12 18:18","pubTimestamp":1781259493,"startTime":"0","endTime":"0","summary":"美银全球研究（BofA Global Research）宣布，对生物技术公司Avalo Therapeutics Inc启动研究覆盖，并给予其股票“买入”评级。该机构同时设定了35美元的目标股价，预示着对公司未来前景的积极展望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117683293","title":"异动解读 | 分析师下调目标价，Avalo Therapeutics盘中大跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117683293","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117683293?lang=zh_cn&edition=full","pubTime":"2026-05-15 03:53","pubTimestamp":1778788388,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc（AVTX）今日盘中股价大幅下挫5.11%，引起了投资者的关注。消息面上，多家华尔街投行在今日发布了针对该公司的研究报告并调整了其目标价，其中H.C. Wainwright将目标价从40美元下调至35美元，Wedbush将目标价从40美元下调至34美元，这两项关键的下调操作可能影响了市场信心，成为股价下跌的主要压力。尽管瑞穗证券将目标价从39美元上调至45美元，但整体上分析师意见出现分歧，且下调目标价的行动对市场情绪产生了更直接的影响，导致该股在交易时段内承压走低。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193194536","title":"Avalo Therapeutics 现有现金及等价物与短期投资预计可支持运营至2029年","url":"https://stock-news.laohu8.com/highlight/detail?id=1193194536","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193194536?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:08","pubTimestamp":1778670499,"startTime":"0","endTime":"0","summary":"根据公司披露的财务信息，Avalo Therapeutics Inc. 目前的现金、现金等价物以及短期投资总额，预计足以支持其日常运营及研发活动持续进行至2029年。这一充裕的财务缓冲为公司推进其临床阶段项目提供了关键的资金保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164515843","title":"Avalo Therapeutics盘中飙升43.5% 皮肤病药物中期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1164515843","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164515843?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:48","pubTimestamp":1778064539,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc (AVTX) 股价在盘前交易时段大幅跃升43.5%，此前该公司宣布其针对皮肤病的在研药物已成功达成中期临床试验的主要目标。\n这一积极数据显著提振了投资者信心，预示着该候选疗法在后续开发中具备良好潜力。受此消息影响，公司股价出现强劲反弹，市场反应热烈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162661396","title":"Avalo Therapeutics Inc二期Lotus试验达成主要终点 第16周应答率分别达42.2%与42.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162661396","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162661396?lang=zh_cn&edition=full","pubTime":"2026-05-06 04:08","pubTimestamp":1778011681,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc宣布，其二期Lotus临床试验已成功达成主要研究终点。数据显示，在第16周的治疗评估节点，试验组患者呈现出显著临床应答，两组患者的应答率分别达到42.2%和42.9%。这一突破性进展标志着该公司在相关治疗领域取得重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100464275","title":"Avalo Therapeutics Inc公布二期莲花试验关键次要终点统计学显著获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1100464275","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100464275?lang=zh_cn&edition=full","pubTime":"2026-05-06 04:03","pubTimestamp":1778011438,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc最新披露的数据显示，其二期莲花试验在关键次要终点方面取得了具有统计学意义的显著临床获益。这一突破性进展为后续临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175268729","title":"Avalo Therapeutics公司公布II期Lotus试验结果：Abdakibart耐受性良好，安全性特征优异","url":"https://stock-news.laohu8.com/highlight/detail?id=1175268729","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175268729?lang=zh_cn&edition=full","pubTime":"2026-05-06 04:03","pubTimestamp":1778011415,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc宣布，其候选药物Abdakibart在II期Lotus临床试验中展现出良好的耐受性，并具有优异的安全性特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103047353","title":"Avalo Therapeutics公布阿布达基巴特（Avtx-009）治疗中重度化脓性汗腺炎二期莲花试验积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1103047353","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103047353?lang=zh_cn&edition=full","pubTime":"2026-05-06 04:01","pubTimestamp":1778011278,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc (AVTX) 宣布，其针对中重度化脓性汗腺炎的研究药物阿布达基巴特（研发代号：Avtx-009），在二期莲花临床试验中取得了积极的顶线结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136316695","title":"Avalo Therapeutics达成里程碑付款买断协议 优化资本结构","url":"https://stock-news.laohu8.com/highlight/detail?id=1136316695","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136316695?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:15","pubTimestamp":1777374917,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司Avalo Therapeutics Inc  近日宣布，就2024年3月收购AlmataBio公司所涉条款达成里程碑付款买断协议。通过该选择权，Avalo可选择以现金、普通股或组合形式支付512.5万美元，替代原定在III期临床试验首例患者给药时需支付的1500万美元或有里程碑款项。通过前置部分付款义务，Avalo在保留研发推进主动权的同时，有效规避了未来可能产生的高额里程碑付款风险。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","LENZ","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162862694","title":"Avalo Therapeutics Inc以225万美元购得Almatabio前股东期权","url":"https://stock-news.laohu8.com/highlight/detail?id=1162862694","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162862694?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:14","pubTimestamp":1777374859,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc（股票代码：AVTX）近日与生物技术公司Almatabio的前股东达成一项期权协议。根据协议条款，Avalo将支付225万美元，以获得特定资产或技术的优先认购权。\n这笔交易体现了Avalo在拓展其治疗管线方面的战略布局。通过支付期权费用，公司得以在未来特定条件下行使收购权利，为潜在的技术整合或产品开发预留空间。\n此次期权协议的金额虽不大，但反映出生物科技领域企业通过灵活的交易结构强化研发实力的趋势。市场关注Avalo是否会基于该期权进一步推进相关领域的业务部署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147664626","title":"Avalo Therapeutics Inc将于2026年4月26日起五个工作日内向证券持有人代表支付225万美元——美国证券交易委员会文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1147664626","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147664626?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:09","pubTimestamp":1777374582,"startTime":"0","endTime":"0","summary":"根据最新提交至美国证券交易委员会的文件披露，生物制药公司Avalo Therapeutics Inc已明确支付时间表，其需在2026年4月26日之后的五个工作日内，向证券持有人代表支付总额达225万美元的款项。\n该笔资金的支付时限与具体金额在监管文件中被重点标注，体现出公司对股东权益保障的合规承诺。作为专注于炎症性疾病与免疫学领域创新疗法开发的临床阶段企业，此次支付安排或与其近期资本运作及股东协议条款的履行密切相关。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518203857","title":"Avalo Therapeutics, Inc.盘中异动 快速上涨6.19%报8.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518203857","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518203857?lang=zh_cn&edition=full","pubTime":"2025-03-11 00:20","pubTimestamp":1741623628,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日00时20分，Avalo Therapeutics, Inc.股票出现异动，股价快速拉升6.19%。Avalo Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.32%。其相关个股中，Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Aeon Biopharma, Inc.、Scisparc Ltd.较为活跃，换手率分别为3705.04%、3188.84%、944.79%，振幅较大的相关个股有Protagenic Therapeutics Inc C/Wts 29/04/2026 、Aeon Biopharma, Inc.、Scisparc Ltd.，振幅分别为88.14%、78.32%、49.87%。Avalo Therapeutics, Inc.公司简介：Avalo Therapeutics Inc 是一家临床阶段生物技术公司，专注于免疫失调的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311002028abf33936&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311002028abf33936&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVTX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517194347","title":"Avalo Therapeutics, Inc.盘中异动 下午盘急速拉升5.44%报7.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517194347","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517194347?lang=zh_cn&edition=full","pubTime":"2025-03-07 03:17","pubTimestamp":1741288628,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日03时17分，Avalo Therapeutics, Inc.股票出现异动，股价快速拉升5.44%。Avalo Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.71%。其相关个股中，Plus Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大，Aeon Biopharma, Inc.、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃，换手率分别为5013.44%、3925.30%、257.97%，振幅较大的相关个股有Plus Therapeutics, Inc.、Surrozen Inc C/Wts 01/08/2031 、Tonix Pharmaceuticals Holding Corp.，振幅分别为133.94%、125.28%、71.44%。Avalo Therapeutics, Inc.公司简介：Avalo Therapeutics Inc 是一家临床阶段生物技术公司，专注于免疫失调的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307031709963c7e4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307031709963c7e4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVTX","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517279985","title":"Avalo Therapeutics, Inc.盘中异动 股价大涨6.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517279985","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517279985?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:23","pubTimestamp":1741119819,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时23分，Avalo Therapeutics, Inc.股票出现异动，股价急速上涨6.71%。Avalo Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.27%。其相关个股中，Rapport Therapeutics, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Aeon Biopharma, Inc.、Protagenic Therapeutics, Inc.、Windtree Therapeutics, Inc.较为活跃，换手率分别为1327.56%、1257.46%、1219.64%，振幅较大的相关个股有Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Plus Therapeutics, Inc.，振幅分别为122.48%、68.89%、68.09%。Avalo Therapeutics, Inc.公司简介：Avalo Therapeutics Inc 是一家临床阶段生物技术公司，专注于免疫失调的治疗。Avalo 的产品线还包括 quisovalimab和 AVTX-008。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305042339989bfcc4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305042339989bfcc4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVTX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516308986","title":"Avalo Therapeutics, Inc.盘中异动 早盘股价大跌5.61%报6.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516308986","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516308986?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:12","pubTimestamp":1741014730,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时12分，Avalo Therapeutics, Inc.股票出现异动，股价大幅跳水5.61%。Avalo Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Entero Therapeutics Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为1475.56%、131.29%、106.66%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为177.97%、70.53%、48.34%。Avalo Therapeutics, Inc.公司简介：Avalo Therapeutics Inc 是一家临床阶段生物技术公司，专注于免疫失调的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303231210a25d4c4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303231210a25d4c4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVTX","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514320141","title":"Avalo Therapeutics, Inc.盘中异动 早盘股价大涨5.61%报6.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320141","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514320141?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753086,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Avalo Therapeutics, Inc.股票出现波动，股价快速上涨5.61%。Avalo Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Tc Biopharm  Plc C/Wts 10/02/2028 、Anaptysbio, Inc.、Enveric Biosciences, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Virpax Pharmaceuticals, Inc.、Enveric Biosciences, Inc.较为活跃，换手率分别为480.36%、239.12%、55.70%，振幅较大的相关个股有Trevi Therapeutics, Inc.、Enanta Pharmaceuticals, Inc.、Aardvark Therapeutics, Inc.，振幅分别为7.11%、6.58%、6.22%。Avalo Therapeutics, Inc.公司简介：Avalo Therapeutics Inc 是一家临床阶段生物技术公司，专注于免疫失调的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223126abe0ea2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223126abe0ea2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514861570","title":"Avalo Therapeutics, Inc.盘中异动 快速跳水5.10%报6.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514861570","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514861570?lang=zh_cn&edition=full","pubTime":"2025-02-27 03:11","pubTimestamp":1740597074,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日03时11分，Avalo Therapeutics, Inc.股票出现波动，股价快速跳水5.10%。Avalo Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.60%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Nkgen Biotech Inc C/Wts 31/05/2028涨幅较大，Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃，换手率分别为6533.97%、289.89%、257.10%，振幅较大的相关个股有Enveric Biosciences, Inc.、Renovaro Inc.、Organovo Holdings, Inc.，振幅分别为194.07%、81.11%、52.76%。Avalo Therapeutics, Inc.公司简介：Avalo Therapeutics Inc 是一家临床阶段生物技术公司，专注于免疫失调的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227031114abde2a1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227031114abde2a1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514090328","title":"Avalo Therapeutics, Inc.盘中异动 急速下挫6.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090328","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514090328?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:32","pubTimestamp":1740493959,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时32分，Avalo Therapeutics, Inc.股票出现异动，股价大幅跳水6.17%。Avalo Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。其相关个股中，Moleculin Biotech, Inc.、Silexion Therapeutics Corp、Adial Pharmaceuticals, Inc涨幅较大，Gt Biopharma, Inc.、Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc较为活跃，换手率分别为751.75%、467.59%、235.58%，振幅较大的相关个股有Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp、Maze Therapeutics, Inc.，振幅分别为20.51%、14.67%、8.87%。Avalo Therapeutics, Inc.公司简介：Avalo Therapeutics Inc 是一家临床阶段生物技术公司，专注于免疫失调的治疗。Avalo 的产品线还包括 quisovalimab和 AVTX-008。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223239962ff292&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223239962ff292&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avalotx.com","stockEarnings":[{"period":"1week","weight":0.0417},{"period":"1month","weight":0.4695},{"period":"3month","weight":0.3359},{"period":"6month","weight":0.1251},{"period":"1year","weight":3.0526},{"period":"ytd","weight":0.06}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":0.0138},{"period":"3month","weight":0.1061},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.2047},{"period":"ytd","weight":0.0965}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avalo Therapeutics, Inc.于2011年1月31日在特拉华州注册成立。该公司是一家临床阶段的生物技术公司，完全致力于开发基于IL-1β的免疫介导的炎症性疾病治疗方法。公司的主要候选产品abdakibart（AVTX-009），一种抗IL-1β单抗（“MAB”），正处于化脓性汗腺炎（“HS”）的2期临床试验中。该公司还在探索更多机会，以在存在大量未满足需求的流行适应症方面产生影响。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.063135},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.010519},{"month":3,"riseRate":0.272727,"avgChangeRate":0.280205},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.088879},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.046144},{"month":6,"riseRate":0.727273,"avgChangeRate":0.024954},{"month":7,"riseRate":0.545455,"avgChangeRate":0.026559},{"month":8,"riseRate":0.6,"avgChangeRate":-0.034606},{"month":9,"riseRate":0.6,"avgChangeRate":0.04604},{"month":10,"riseRate":0.6,"avgChangeRate":0.161359},{"month":11,"riseRate":0.4,"avgChangeRate":-0.050828},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.047903}],"exchange":"NASDAQ","name":"Avalo Therapeutics Inc","nameEN":"Avalo Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avalo Therapeutics Inc(AVTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Avalo Therapeutics Inc(AVTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Avalo Therapeutics Inc,AVTX,Avalo Therapeutics Inc股票,Avalo Therapeutics Inc股票老虎,Avalo Therapeutics Inc股票老虎国际,Avalo Therapeutics Inc行情,Avalo Therapeutics Inc股票行情,Avalo Therapeutics Inc股价,Avalo Therapeutics Inc股市,Avalo Therapeutics Inc股票价格,Avalo Therapeutics Inc股票交易,Avalo Therapeutics Inc股票购买,Avalo Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avalo Therapeutics Inc(AVTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Avalo Therapeutics Inc(AVTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}